326030.KS
SK Biopharmaceuticals Co., Ltd.
KSC · Healthcare · Biotechnology · KR
KRW 86,400.00
+0.12%Year over year
Reported trailing growth
- Revenue
- +38.9%
- EBITDA
- +0.5%
- EBIT
- +105.5%
- EPS
- +51.6%
- Free cash flow
- +173.4%
- Operating cash flow
- +143.7%
Forward estimates
Based on analyst estimates
- Revenue
- +26.9%
- EBITDA
- -18.9%
- EPS
- -59.3%
Three-year CAGR
- Revenue
- +42.1%
- EBITDA
- +119.3%
- EBIT
- +111.7%
- Net income
- +10.9%
- EPS
- +11.1%
- Free cash flow
- +113.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026